特藥非專利市場－全球產業規模、佔有率、趨勢、機會、預測：依給藥途徑、適應症、分銷管道、地區和競爭格局分類，2021-2031年

全球特藥非專利市場預計將經歷顯著成長，從 2025 年的 566.9 億美元成長到 2031 年的 991.2 億美元，複合年成長率為 9.76%。

該領域專注於高度複雜藥物的生物等效性，例如注射劑和生物製藥，這些藥物用於治療癌症和自體免疫疾病等慢性病和罕見疾病，通常需要特殊處理。市場擴張的根本驅動力是慢性病盛行率的不斷上升以及控制醫療成本的迫切需求，尤其是在主要原廠藥專利到期下。價格合理的替代藥物具有顯著的經濟價值，預計到2024年，學名藥和生物相似藥將為美國醫療保健系統節省4,670億美元。

市場促進因素

全球特藥非專利市場的主要促進因素是專利到期。 2025年至2030年間，價值約2,360億美元的藥品將面臨學名藥和生物類似藥的競爭，這為非專利生產商提供了絕佳機會，使其能夠將生物等效替代品推向市場，並減輕患者因使用昂貴的原研藥而承受的經濟負擔。全球複雜慢性病和罕見疾病的日益增加進一步推動了市場需求，據報道，到2023年，76.4%的美國成年人患有一種或多種慢性病。這促使像山德士這樣的製藥公司在全球擴展業務，為100多個國家的9.02億多名患者提供治療。

市場挑戰

儘管全球特種非專利市場擁有強勁的成長潛力，但仍面臨許多挑戰，主要源自於嚴格的監管環境。與常見的口服製劑不同，開發生物等效的注射劑和生物製藥需要複雜的生產過程和大規模的臨床試驗，這帶來了巨大的資金和技術負擔。這些高標準限制了具備研發能力的生產商數量，造成了瓶頸，延緩了經濟有效的治療方法的推出，並阻礙了市場擴張。一項頗具洞察力的統計數據預測，未來十年將有118種生物製藥失去專利保護，而到2025年，其中只有12種生物製劑的生物類似藥正在研發中。這凸顯了監管的複雜性和高昂的研發成本如何阻礙了新計畫的推出。

市場趨勢

受這些市場動態的驅動，一個關鍵趨勢是，市場參與者正積極尋求策略聯盟和併購，共用風險、利用監管合規和全球分銷方面的專業知識，並克服生物類似藥和特種注射劑商業化過程中涉及的巨大資金和技術複雜性。這種整合正在加速市場准入並擴大商業性覆蓋範圍，一個典型的例子是，Biocon Biologics在整合Viatris的生物相似藥業務後，年銷售額超過10億美元。同時，製藥公司正策略性地將其產品組合擴展到生物相似藥、胜肽類藥物和長效注射劑等複雜的學名藥領域，以應對口服固體製劑的價格壓力，並在競爭不那麼激烈的領域確保更永續的收入來源。 Sandoz將其全球生物相似藥產品線擴展至28個分子，凸顯了這項轉變。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球特藥非專利市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 給藥途徑（注射、口服、其他）
  • 依疾病類型分類的適應症（腫瘤、自體免疫疾病、感染疾病、其他）
  • 分銷通路（零售藥局、專科藥局、醫院藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美特藥學非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲特藥非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區特藥非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲特藥非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美特藥非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球特藥非專利市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Teva Pharmaceuticals Industries Ltd
• Viatris Inc.
• Novartis AG
• Hikma Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories Ltd.
• Endo Pharmaceuticals Inc.
• Apotex Corporation
• Sun Pharmaceutical Industries Ltd
• STADA Arzneimittel AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Specialty Generics Market is set for substantial growth, projected to increase from USD 56.69 Billion in 2025 to USD 99.12 Billion by 2031 at a 9.76% CAGR. This sector focuses on bioequivalent versions of highly complex pharmaceutical products, such as injectables and biologics, used to treat chronic or rare conditions like cancer and autoimmune disorders, often requiring specialized handling. The market's expansion is fundamentally driven by the escalating prevalence of chronic diseases and the critical imperative for healthcare cost containment, particularly following the patent expiration of major originator drugs. The economic value of affordable alternatives is significant, with generic and biosimilar medicines saving the U.S. healthcare system $467 billion in 2024.

Market Driver

A major catalyst for the Global Specialty Generics Market is the impending patent cliff, with approximately $236 billion worth of pharmaceutical products facing generic and biosimilar competition between 2025 and 2030, creating immense opportunities for generic manufacturers to introduce bioequivalent alternatives and alleviate the financial burden of expensive originator therapies. The global increase in complex chronic and rare diseases further amplifies demand, with 76.4% of U.S. adults reporting one or more chronic conditions in 2023, driving manufacturers like Sandoz to expand global operations, having delivered over 902 million patient treatments across more than 100 countries.

Market Challenge

Despite this robust growth potential, the Global Specialty Generics Market faces considerable challenges, primarily stemming from a rigorous regulatory landscape. Unlike standard oral formulations, the development of bioequivalent injectables and biologics requires intricate manufacturing processes and extensive clinical trials, imposing significant financial and technical burdens. These elevated standards limit the number of capable manufacturers, creating a bottleneck that delays the availability of cost-effective treatments and restricts market expansion. A telling statistic reveals that while 118 biologics are expected to lose patent exclusivity over the next decade, only 12 of these molecules had biosimilars in development in 2025, highlighting how regulatory complexity and high development costs deter the initiation of new programs.

Market Trends

In response to these market dynamics, a key trend sees market players increasingly forming strategic alliances and engaging in mergers to share risks, leverage expertise in regulatory affairs and global distribution, and navigate the substantial capital and technical complexities of commercializing biosimilars and specialty injectables. This consolidation accelerates market entry and expands commercial reach, as exemplified by Biocon Biologics exceeding $1 billion in annual revenue post-integration of Viatris' biosimilars business. Concurrently, manufacturers are strategically expanding their portfolios into complex generics like biosimilars, peptides, and long-acting injectables to counter pricing pressures on oral solid dosages and secure more sustainable revenue streams with less competitive intensity, a shift evidenced by Sandoz's global biosimilar pipeline growing to 28 molecules.

Key Market Players

• Teva Pharmaceuticals Industries Ltd
• Viatris Inc.
• Novartis AG
• Hikma Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories Ltd.
• Endo Pharmaceuticals Inc.
• Apotex Corporation
• Sun Pharmaceutical Industries Ltd
• STADA Arzneimittel AG

Report Scope

In this report, the Global Specialty Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specialty Generics Market, By Route of Administration

• Injectable
• Oral
• others

Specialty Generics Market, By Indication

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• others

Specialty Generics Market, By Distribution Channel

• Retail Pharmacies
• Specialty Pharmacies
• Hospital Pharmacies

Specialty Generics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specialty Generics Market.

Available Customizations:

Global Specialty Generics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specialty Generics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Injectable, Oral, others)
  • 5.2.2. By Indication (Oncology, Autoimmune Diseases, Infectious Diseases, others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Specialty Generics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Specialty Generics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Specialty Generics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Specialty Generics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Specialty Generics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Specialty Generics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Specialty Generics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Specialty Generics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Specialty Generics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Specialty Generics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Specialty Generics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Specialty Generics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Specialty Generics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Specialty Generics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Specialty Generics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Specialty Generics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Specialty Generics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Specialty Generics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Specialty Generics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Specialty Generics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. South America Specialty Generics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Specialty Generics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Specialty Generics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Specialty Generics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Specialty Generics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceuticals Industries Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Viatris Inc.
• 15.3. Novartis AG
• 15.4. Hikma Pharmaceuticals PLC
• 15.5. Bausch Health Companies Inc.
• 15.6. Dr. Reddy's Laboratories Ltd.
• 15.7. Endo Pharmaceuticals Inc.
• 15.8. Apotex Corporation
• 15.9. Sun Pharmaceutical Industries Ltd
• 15.10. STADA Arzneimittel AG

16. Strategic Recommendations

17. About Us & Disclaimer